{"id":"palbociclib-pd-0332991","safety":{"commonSideEffects":[{"rate":"30-40%","effect":"Fatigue"},{"rate":"20-30%","effect":"Nausea"},{"rate":"20-30%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Vomiting"},{"rate":"10-20%","effect":"Leukopenia"},{"rate":"10-20%","effect":"Neutropenia"},{"rate":"5-10%","effect":"Thrombocytopenia"},{"rate":"5-10%","effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting CDK4/6, palbociclib slows down the growth and division of cancer cells. This can help to slow the progression of certain types of cancer. Palbociclib is often used in combination with other medications to treat hormone receptor-positive, HER2-negative breast cancer.","oneSentence":"Palbociclib is a CDK4/6 inhibitor that works by blocking the activity of cyclin-dependent kinases 4 and 6, which are involved in cell cycle progression.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:25:33.589Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hormone receptor-positive, HER2-negative breast cancer"}]},"trialDetails":[{"nctId":"NCT04439201","phase":"PHASE2","title":"Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-05-31","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm","enrollment":40},{"nctId":"NCT02159755","phase":"PHASE1","title":"Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-08-13","conditions":"Recurrent Mantle Cell Lymphoma","enrollment":28},{"nctId":"NCT06126276","phase":"PHASE2","title":"Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-05-07","conditions":"Malignant Female Reproductive System Neoplasm, Malignant Solid Neoplasm, Recurrent Malignant Female Reproductive System Neoplasm","enrollment":70},{"nctId":"NCT04216576","phase":"NA","title":"A Study of the Use of Text Message Reminders to Take Palbociclib","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2019-12-27","conditions":"Breast Cancer","enrollment":45},{"nctId":"NCT05564377","phase":"PHASE2","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-04-07","conditions":"Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8","enrollment":2900},{"nctId":"NCT03297606","phase":"PHASE2","title":"Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)","status":"RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2018-03-23","conditions":"Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors","enrollment":720},{"nctId":"NCT05554367","phase":"PHASE2","title":"Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-12-13","conditions":"Exocrine Pancreas Carcinoma, Malignant Solid Neoplasm, Ovarian Low Grade Serous Adenocarcinoma","enrollment":199},{"nctId":"NCT06390839","phase":"PHASE2","title":"Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH - Subprotocol Z1C)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-03-22","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma","enrollment":43},{"nctId":"NCT02465060","phase":"PHASE2","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-08-17","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma","enrollment":6452},{"nctId":"NCT07492641","phase":"PHASE3","title":"BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease","status":"NOT_YET_RECRUITING","sponsor":"BeOne Medicines","startDate":"2026-05-11","conditions":"HR+/HER2- Breast Cancer","enrollment":1056},{"nctId":"NCT05039177","phase":"PHASE1, PHASE2","title":"A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies","status":"COMPLETED","sponsor":"Erasca, Inc.","startDate":"2021-09-20","conditions":"Metastatic Colorectal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma","enrollment":101},{"nctId":"NCT07493291","phase":"","title":"Effectiveness and Safety of Palbociclib: Brand vs. Generic in Iraqi Stage IV Hormone Receptor-positive / Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer Patients: A Comparative Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Al-Mustansiriyah University","startDate":"2025-09-07","conditions":"Brest Cancer","enrollment":100},{"nctId":"NCT07123090","phase":"PHASE2","title":"A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma","status":"RECRUITING","sponsor":"Stephanie Berg","startDate":"2025-11-24","conditions":"Metastatic Renal Cell Carcinoma, Metastatic Renal Cancer, Renal Cell Carcinoma","enrollment":25},{"nctId":"NCT07491380","phase":"NA","title":"Validation of Capillary Microsampling for Therapeutic Drug Monitoring of CDK4/6 Inhibitors in Breast Cancer Patients (TDHOME)","status":"NOT_YET_RECRUITING","sponsor":"Institut Curie","startDate":"2026-05-15","conditions":"Breast Cancer","enrollment":90},{"nctId":"NCT07487129","phase":"PHASE4","title":"Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2024-08-25","conditions":"Breast Cancer","enrollment":206},{"nctId":"NCT07347600","phase":"","title":"A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2026-01-21","conditions":"Locally Advanced Breast Cancer, Metastatic Breast Cancer","enrollment":500},{"nctId":"NCT07174336","phase":"PHASE3","title":"A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-12-22","conditions":"Breast Neoplasms, Neoplasm Metastasis","enrollment":920},{"nctId":"NCT02693535","phase":"PHASE2","title":"TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer","status":"RECRUITING","sponsor":"American Society of Clinical Oncology","startDate":"2016-03-14","conditions":"Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors","enrollment":4200},{"nctId":"NCT07405164","phase":"PHASE3","title":"Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-03-23","conditions":"Von Hippel-Lindau Disease, Carcinoma, Renal Cell","enrollment":450},{"nctId":"NCT03573648","phase":"PHASE2","title":"Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2018-11-13","conditions":"Breast Cancer","enrollment":33},{"nctId":"NCT06377852","phase":"PHASE3","title":"The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study","status":"RECRUITING","sponsor":"American Society of Clinical Oncology","startDate":"2024-10-29","conditions":"Metastatic Breast Cancer","enrollment":500},{"nctId":"NCT04653740","phase":"NA","title":"Omic Technologies to Track Resistance to Palbociclib in Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Oscar Lambret","startDate":"2020-09-08","conditions":"Advanced Breast Cancer","enrollment":25},{"nctId":"NCT04191499","phase":"PHASE2, PHASE3","title":"A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-01-29","conditions":"Breast Cancer","enrollment":325},{"nctId":"NCT06997029","phase":"PHASE1","title":"A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-08-01","conditions":"Advanced Solid Tumor, Advanced Breast Cancer, Advanced Ovarian Cancer","enrollment":234},{"nctId":"NCT04802759","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-06-22","conditions":"Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer","enrollment":316},{"nctId":"NCT03424005","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2018-03-30","conditions":"Metastatic Breast Cancer","enrollment":792},{"nctId":"NCT04693468","phase":"PHASE1","title":"Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-12-01","conditions":"Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm","enrollment":111},{"nctId":"NCT06843967","phase":"PHASE1, PHASE2","title":"A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-02-19","conditions":"Well Differentiated Liposarcoma, Dedifferentiated Liposarcoma, Liposarcoma","enrollment":54},{"nctId":"NCT06736704","phase":"PHASE1, PHASE2","title":"SNV4818 in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Pikavation Therapeutics, Inc.","startDate":"2025-02-20","conditions":"Advanced Solid Tumors","enrollment":320},{"nctId":"NCT06380751","phase":"PHASE3","title":"Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-08-01","conditions":"Advanced Breast Cancer","enrollment":500},{"nctId":"NCT05627232","phase":"PHASE1","title":"Tazemetostat and Palbociclib With CPX-351for R/R AML","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2023-08-28","conditions":"Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":24},{"nctId":"NCT04862663","phase":"PHASE3","title":"Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2021-05-10","conditions":"Locally Advanced (Inoperable) or Metastatic Breast Cancer","enrollment":895},{"nctId":"NCT02896335","phase":"PHASE2","title":"Palbociclib and Pembrolizumab In Central Nervous System Metastases","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2017-02-02","conditions":"Metastatic Malignant Neoplasm to Brain, Recurrent Brain Metastases, Progressive Brain Metastases","enrollment":45},{"nctId":"NCT03006172","phase":"PHASE1","title":"To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2016-12-13","conditions":"Breast Cancer, Solid Tumor","enrollment":200},{"nctId":"NCT04931342","phase":"PHASE2","title":"A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-10-07","conditions":"Ovarian Cancer","enrollment":176},{"nctId":"NCT03446157","phase":"PHASE2","title":"Palbociclib and Cetuximab in Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2018-03-23","conditions":"Cancer of the Colon, Colon Cancer, Colon Neoplasms","enrollment":24},{"nctId":"NCT06065748","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-12-11","conditions":"Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer","enrollment":1050},{"nctId":"NCT02905318","phase":"PHASE2","title":"Palbociclib in Patients With Metastatic Castration-Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2017-07-04","conditions":"Prostate Cancer","enrollment":19},{"nctId":"NCT05665361","phase":"PHASE1, PHASE2","title":"Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-04-24","conditions":"Advanced Clear Cell Renal Carcinoma (Ccrcc), Papillary Renal Cell Carcinoma (Prcc)","enrollment":100},{"nctId":"NCT03531645","phase":"PHASE2","title":"Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-08-13","conditions":"Malignant Neoplasms of Female Genital Organs","enrollment":18},{"nctId":"NCT05768139","phase":"PHASE1, PHASE2","title":"First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2023-04-17","conditions":"Breast Cancer, Solid Tumors, Adult","enrollment":720},{"nctId":"NCT06486883","phase":"PHASE2","title":"Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype","status":"RECRUITING","sponsor":"MedSIR","startDate":"2025-06-30","conditions":"Advanced Breast Cancer, Advanced Breast Carcinoma, Hormone Receptor Positive Breast Carcinoma","enrollment":200},{"nctId":"NCT06760637","phase":"PHASE3","title":"Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-01-06","conditions":"Breast Cancer","enrollment":1020},{"nctId":"NCT04498481","phase":"","title":"TREATMENT AND MONITORING PATTERNS AND CLINICAL OUTCOMES IN PATIENTS RECEIVING PALBOCICLIB COMBINATION TREATMENT (WITH AI OR FULVESTRANT) FOR HR+/HER2- A/MBC IN A COMMUNITY ONCOLOGY SETTING.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-03-01","conditions":"Breast Cancer","enrollment":1},{"nctId":"NCT04288089","phase":"PHASE1","title":"A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eisai Inc.","startDate":"2020-04-01","conditions":"Receptors, Estrogen, Genes, Erbb-2, Breast Neoplasms","enrollment":31},{"nctId":"NCT02778685","phase":"PHASE2","title":"Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2016-09-30","conditions":"Metastatic Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7","enrollment":47},{"nctId":"NCT06188520","phase":"PHASE1, PHASE2","title":"A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-12-05","conditions":"ER+ HER2- Advanced Breast Cancer, High-grade Serous Ovarian Cancer (HGSOC)","enrollment":564},{"nctId":"NCT04546009","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-10-09","conditions":"Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer","enrollment":992},{"nctId":"NCT03065062","phase":"PHASE1","title":"Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors","status":"SUSPENDED","sponsor":"Dana-Farber Cancer Institute","startDate":"2017-02-28","conditions":"Lung Cancer Squamous Cell, Solid Tumors, Head & Neck Cancer","enrollment":75},{"nctId":"NCT03332797","phase":"PHASE1","title":"A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2017-11-24","conditions":"Breast Cancer","enrollment":181},{"nctId":"NCT02947685","phase":"PHASE3","title":"Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance Foundation Trials, LLC.","startDate":"2017-06-21","conditions":"HER-2 Positive Breast Cancer, Estrogen Receptor Positive Breast Cancer","enrollment":518},{"nctId":"NCT07407439","phase":"","title":"Real-world Studies of CDK4/6 Inhibitors","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-06-01","conditions":"Breast Cancer","enrollment":245},{"nctId":"NCT03170206","phase":"PHASE1","title":"Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2017-05-31","conditions":"Lung Cancer","enrollment":34},{"nctId":"NCT02624973","phase":"PHASE2","title":"PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Haukeland University Hospital","startDate":"2016-04-15","conditions":"Breast Cancer","enrollment":200},{"nctId":"NCT02499146","phase":"PHASE1","title":"Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2015-09-11","conditions":"Advanced Breast Cancer","enrollment":26},{"nctId":"NCT05238922","phase":"PHASE1","title":"Study of INCB123667 in Subjects With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2022-07-05","conditions":"Solid Tumors","enrollment":604},{"nctId":"NCT05909397","phase":"PHASE3","title":"Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2023-08-09","conditions":"Breast Cancer","enrollment":59},{"nctId":"NCT04072952","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Arvinas Estrogen Receptor, Inc.","startDate":"2019-08-05","conditions":"Breast Cancer","enrollment":217},{"nctId":"NCT02513394","phase":"PHASE3","title":"PALbociclib CoLlaborative Adjuvant Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance Foundation Trials, LLC.","startDate":"2015-08","conditions":"Breast Cancer","enrollment":5796},{"nctId":"NCT05501886","phase":"PHASE3","title":"Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celcuity Inc","startDate":"2022-12-08","conditions":"Breast Cancer","enrollment":701},{"nctId":"NCT03155620","phase":"PHASE2","title":"Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-07-31","conditions":"Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma","enrollment":1376},{"nctId":"NCT06757634","phase":"PHASE3","title":"Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)","status":"RECRUITING","sponsor":"Celcuity Inc","startDate":"2025-07-24","conditions":"Breast Cancer","enrollment":674},{"nctId":"NCT07178743","phase":"","title":"Emulation of the PALOMA-2 Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2025-07-14","conditions":"Advanced Breast Cancer","enrollment":6097},{"nctId":"NCT03616587","phase":"PHASE1","title":"Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-10-11","conditions":"ER+ HER2- Advanced Breast Cancer","enrollment":396},{"nctId":"NCT05694871","phase":"PHASE2","title":"Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2023-06-07","conditions":"Advanced Dedifferentiated Liposarcoma, Locally Advanced Dedifferentiated Liposarcoma, Metastatic Dedifferentiated Liposarcoma","enrollment":77},{"nctId":"NCT05696626","phase":"PHASE3","title":"Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation","status":"RECRUITING","sponsor":"Sermonix Pharmaceuticals Inc.","startDate":"2023-10-31","conditions":"Metastatic Breast Cancer","enrollment":500},{"nctId":"NCT05468697","phase":"PHASE1, PHASE2","title":"A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-08-10","conditions":"Renal Cell Carcinoma","enrollment":60},{"nctId":"NCT04360941","phase":"PHASE1","title":"PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"Royal Marsden NHS Foundation Trust","startDate":"2020-08-11","conditions":"Triple Negative Breast Cancer, Locally Advanced Breast Cancer, Recurrent Breast Cancer","enrollment":45},{"nctId":"NCT02668666","phase":"PHASE2","title":"Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer","status":"COMPLETED","sponsor":"Oana Danciu, MD","startDate":"2017-02-01","conditions":"Hormone Receptor Positive Malignant Neoplasm of Breast, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Estrogen Receptor Positive Breast Cancer","enrollment":49},{"nctId":"NCT04964934","phase":"PHASE3","title":"Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-06-30","conditions":"ER-Positive HER2-Negative Breast Cancer","enrollment":315},{"nctId":"NCT07340658","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of Letrozole SIE Compared With Femara® (Both Combined With the CDK4/6 Inhibitor Palbociclib) in Postmenopausal Women With HR-Positive, HER2-Negative, Advanced Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Rovi Pharmaceuticals Laboratories","startDate":"2026-05","conditions":"Advanced, Metastatic Breast Cancer","enrollment":300},{"nctId":"NCT02264613","phase":"PHASE1, PHASE2","title":"ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas","status":"COMPLETED","sponsor":"Aileron Therapeutics, Inc.","startDate":"2014-10","conditions":"Solid Tumor, Lymphoma, Peripheral T-Cell Lymphoma","enrollment":142},{"nctId":"NCT05826964","phase":"PHASE2","title":"Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2023-06-12","conditions":"Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer","enrollment":24},{"nctId":"NCT03065387","phase":"PHASE1","title":"Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-10-31","conditions":"Advanced Malignant Solid Neoplasm, EGFR Gene Amplification, EGFR Gene Mutation","enrollment":93},{"nctId":"NCT03685331","phase":"PHASE1","title":"HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer","status":"COMPLETED","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2020-10-15","conditions":"Metastatic Breast Cancer, Locally Advanced Breast Cancer, Advanced Breast Cancer","enrollment":9},{"nctId":"NCT07002177","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC","status":"RECRUITING","sponsor":"Forward Pharmaceuticals Co., Ltd.","startDate":"2025-06-01","conditions":"Metastatic Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II","enrollment":196},{"nctId":"NCT02942355","phase":"PHASE2","title":"Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2016-12-07","conditions":"Female Breast Carcinoma, Breast Cancer","enrollment":40},{"nctId":"NCT05563220","phase":"PHASE1, PHASE2","title":"Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Stemline Therapeutics, Inc.","startDate":"2023-01-24","conditions":"Breast Cancer, Metastatic Breast Cancer","enrollment":435},{"nctId":"NCT07037199","phase":"PHASE2","title":"Efficacy and Safety of Trastuzumab Rezetecan Followed by CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2-Low/Ultra-Low Advanced Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-08-18","conditions":"Advanced Breast Cancer","enrollment":45},{"nctId":"NCT07299890","phase":"PHASE2","title":"An Exploratory Study of Pertuzumab and Trastuzumab in Combination With Palbociclib and Exemestane as Neoadjuvant Therapy for Triple-Positive Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Anhui Provincial Cancer Hospital","startDate":"2025-12-20","conditions":"Breast Cancer","enrollment":90},{"nctId":"NCT07300215","phase":"PHASE2","title":"An Exploratory Study on Individualized Neoadjuvant Treatment Regimens for Early HR+/HER2+ Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Bengbu Medical University","startDate":"2025-12-20","conditions":"Breast Cancer","enrollment":60},{"nctId":"NCT05069038","phase":"PHASE2","title":"Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Nebraska","startDate":"2022-03-02","conditions":"Breast Cancer","enrollment":51},{"nctId":"NCT02760030","phase":"PHASE2","title":"Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery","status":"COMPLETED","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2017-02-16","conditions":"Estrogen Receptor and/or Progesterone Receptor Positive, HER2/Neu Negative, Stage IA Breast Cancer","enrollment":14},{"nctId":"NCT03478514","phase":"PHASE2","title":"Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance Foundation Trials, LLC.","startDate":"2018-09-11","conditions":"Mantle Cell Lymphoma, B Cell Lymphoma","enrollment":39},{"nctId":"NCT04563507","phase":"PHASE2","title":"Combined Immunotherapies in Metastatic ER+ Breast Cancer","status":"RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2020-11-12","conditions":"Breast Cancer","enrollment":102},{"nctId":"NCT03784014","phase":"PHASE3","title":"Molecular Profiling of Advanced Soft-tissue Sarcomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2019-10-19","conditions":"Soft Tissue Sarcoma","enrollment":603},{"nctId":"NCT02738866","phase":"PHASE2","title":"Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2016-10-25","conditions":"Metastatic Breast Cancer","enrollment":60},{"nctId":"NCT04671615","phase":"","title":"A Study to Understand the Treatment Patterns and Patients and Their Clinical Outcomes Who Are Taking Palbociclib in a Real Life Setting in Israel.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-12-06","conditions":"Metastatic Breast Cancer","enrollment":559},{"nctId":"NCT01723774","phase":"PHASE2","title":"PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2013-04-10","conditions":"Breast Neoplasms","enrollment":84},{"nctId":"NCT04735367","phase":"","title":"Study to Evaluate Overall Survival in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus Letrozole","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-02-03","conditions":"Breast Cancer","enrollment":42},{"nctId":"NCT06753747","phase":"PHASE1, PHASE2","title":"A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2025-09-10","conditions":"Esophagus Cancer","enrollment":45},{"nctId":"NCT04654208","phase":"","title":"Swedish Ibrance Registries Insights (SIRI)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2020-12-15","conditions":"Malignant Neoplasm of Breast","enrollment":1500},{"nctId":"NCT05226871","phase":"PHASE2","title":"Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2022-07-07","conditions":"Breast Cancer, Head and Neck Cancer","enrollment":35},{"nctId":"NCT02630693","phase":"PHASE2","title":"Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Canadian Cancer Trials Group","startDate":"2016-04-08","conditions":"Breast Cancer","enrollment":180},{"nctId":"NCT06495164","phase":"","title":"A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-06-24","conditions":"Breast Cancer, Malignant Neoplasm of Breast","enrollment":1},{"nctId":"NCT03445637","phase":"","title":"Post Marketing Surveillance Study to Observe Safety and Efficacy of IBRANCE®","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-02-08","conditions":"Breast Neoplasm","enrollment":552},{"nctId":"NCT05266105","phase":"PHASE1","title":"A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Olema Pharmaceuticals, Inc.","startDate":"2021-12-10","conditions":"Breast Cancer","enrollment":60},{"nctId":"NCT03284957","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer","status":"TERMINATED","sponsor":"Sanofi","startDate":"2017-09-20","conditions":"Breast Cancer","enrollment":136},{"nctId":"NCT05867251","phase":"PHASE1, PHASE2","title":"Study of AVZO-021 in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Avenzo Therapeutics, Inc.","startDate":"2023-08-30","conditions":"Advanced Solid Tumor, HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer","enrollment":430},{"nctId":"NCT06086340","phase":"","title":"Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-09-29","conditions":"Breast Cancer","enrollment":779}],"_emaApprovals":[],"_faersSignals":[{"count":6,"reaction":"ASTHENIA"},{"count":5,"reaction":"CONFUSIONAL STATE"},{"count":5,"reaction":"NAUSEA"},{"count":5,"reaction":"NEUTROPHIL COUNT DECREASED"},{"count":5,"reaction":"PLEURAL EFFUSION"},{"count":5,"reaction":"PNEUMONIA"},{"count":4,"reaction":"ACUTE KIDNEY INJURY"},{"count":4,"reaction":"DYSPNOEA"},{"count":4,"reaction":"FAILURE TO THRIVE"},{"count":4,"reaction":"FALL"}],"_approvalHistory":[],"publicationCount":28,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ibrance"],"phase":"phase_3","status":"active","brandName":"Palbociclib PD-0332991","genericName":"Palbociclib PD-0332991","companyName":"GBG Forschungs GmbH","companyId":"gbg-forschungs-gmbh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Palbociclib is a CDK4/6 inhibitor that works by blocking the activity of cyclin-dependent kinases 4 and 6, which are involved in cell cycle progression. Used for Hormone receptor-positive, HER2-negative breast cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}